FindTrial
Sign In

Development of novel immunotherapy using NKT cells for malignant solid tumors in children

Development of novel immunotherapy using NKT cells for malignant solid tumors in children - Development of novel immunotherapy using NKT cells for malignant solid tumors in children

Status
Recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000048076
Enrollment
30
Registered
2022-06-17
Start date
2021-04-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

None listed

Sponsors

Chiba University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Age: Between 20 and 60 years old. 2) Healthy adults with no history of malignant tumors. 3) Those who acknowledge understanding the terms and conditions of this study, and sign study participant agreement of their own free will, after receiving sufficient explanation on participation in this study.

Exclusion criteria

Exclusion criteria: We exclude participants from whom it is difficult to collect blood (in cases where participants' conditions are significantly poor, or it is difficult to collect blood from participants technically).

Design outcomes

Primary

MeasureTime frame
None—

Countries

Japan

Contacts

Public ContactShinichiro Motohashi

Graduate school of Medicine, Chiba University Department of Medical Immunology

motohashi@faculty.chiba-u.jp043-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026